Myocardial Infarction is a major cause of morbidity and mortality due to the frequent occurrence of acute left ventricular (LV) dysfunction that severely complicates prognosis. The conventional treatment, such as nitrates, beta blockers, ACE inhibitors, statins, antiplatelets and anticoagulants, is symptomatic and reduces the possibility of recurrence but does not completely solve the problem of LV dysfunction development. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become a potential novel therapeutic agent outside of glucose-lowering activity in recent years. These agents induce natriuresis, osmotic diuresis, positive myocardial energetics and hemodynamic stabilization, which may lower preload, afterload and maladaptive LV remodelling. The literature support shows that dapagliflozin and empagliflozin, the SGLT2 inhibitors, reduce hospitalization due to heart failure as well as diastolic performance and LV mass index and decrease major adverse cardiovascular events (MACE) in diabetic and nondiabetic patients. There are also cardioprotective effects such as smaller infarct size, mitigated LV remodelling and greater ejection fraction as seen in studies with post-MI patients. This review shows that SGLT2 inhibitors might be beneficial as an adjunctive treatment in acute MI with LV dysfunction because they have a potent effect on both short and long-term outcomes. Additional expansive clinical research should be designed to determine therapeutic effect on this population.

The present study is to develop an extended release tablet of an Antidepressant. It is the serotonin-norepinephrine reuptake inhibitor derivative belongs to cyclohexanol chemical class primarily used in the treatment of major depressive disorder. Extended release dosage forms cover a wide range of prolonged action preparations that provide continuous release of their active ingredients for a specific period of time. Eight formulations (F1 to F8) were designed using Hydroxypropyl methyl cellulose (HPMC K100M), Microcrystalline Cellulose (MCC) as polymers and Hydroxypropyl Cellulose (Klucel), Isopropyl alcohol and Dichloromethane as granulating agent. HPMC was used in different ratios as intragranular and extra granular material. The granules were prepared by using HPMC K100M, Microcrystalline cellulose, drug and the granulating solution. The granules were air dried, subjected for pre-formulation studies and punched using an 8 stationed tablet punching machine bearing 10.5mm die capacity. The punched tablets were evaluated (for weight variation, hardness and friability) and film coated using Instacoat Universal Pink. The film coated tablets were evaluated for weight variation, hardness, drug content and in vitro drug release. Out of the 8 film coated formulations (F1 to F8), the optimized formulation (F8), prepared using 50mg of the drug, 22% HPMC K100M, 28% microcrystalline cellulose and 2% Hydroxypropyl Cellulose as binder. The studies showed 96% invitro drug release in 20 hours and were subjected to short term stability studies.